Connect with us

News

Governor Phil Murphy and ABHI announce UK health tech trade delegation to New Jersey in 2025

Published

on

New Jersey Governor Phil Murphy participated in a roundtable discussion with the Association of British HealthTech Industries (ABHI) and its member companies as part of the Choose New Jersey governor-led economic mission to the United Kingdom.

The visit aimed to strengthen New Jersey’s ties with British partners, with a focus on advancing collaboration in the life sciences and HealthTech sectors, key industries for both economies.

The participation in the roundtable discussion builds on a successful September visit to New Jersey by a cohort from ABHI.

During the roundtable, Governor Murphy engaged with UK HealthTech companies and clinical leaders to explore synergies and growth opportunities within this high-potential sector.

ABHI, the UK’s leading HealthTech trade organisation, was instrumental in these discussions through its US Accelerator program, which supports UK HealthTech companies entering and scaling in the US market.

Governor Murphy said: “New Jersey is committed to fostering global partnerships that drive innovation and economic growth.

“Collaborating with ABHI and UK HealthTech leaders presents a unique opportunity to strengthen our state’s leadership in Life Sciences and HealthTech.

“Together, we’re building a transatlantic pipeline of talent, technology, and ideas that will fuel advancements in healthcare and benefit communities on both sides of the Atlantic.”

The September cohort’s visit to New Jersey laid a strong foundation for this partnership, with engagements across New Jersey’s leading healthcare and research institutions, including Liberty Science Center’s SciTech Scity, Hackensack Meridian Health, Rutgers University, and Rowan University.

These meetings, alongside discussions with leaders from New Jersey’s life sciences, healthcare, and academic sectors, helped shape a plan for ABHI to lead an economic delegation visit to New Jersey in April 2025.

This milestone highlights the growing collaboration between the UK and New Jersey, creating a vital platform for HealthTech companies to forge partnerships that drive innovation, economic growth, and advancements in healthcare for both regions.

“The collaboration between the UK and New Jersey is only beginning,” said Paul Benton, Managing Director, International at ABHI.

“With our U.S. Accelerator planning a delegation to New Jersey in 2025, this is a fantastic opportunity for UK business leaders to foster closer working relationships that benefit the health and wealth of those in both markets.”

The UK roundtable included prominent clinical leaders from across London, such as UCL Partners, Imperial College London, Barts Health NHS Trust, and the Howard de Walden Estate, which manages the Harley Street Health District.

Mark Kildea, Chief Executive of The Howard de Walden Estate, noted that “London has amazing healthcare capabilities and it is important that key stakeholders examine how they can improve patient care and outcomes.

“Investment, trade, and the sharing of best practices are critical in this regard, and so it is with great pleasure that we collaborate with our friends in New Jersey to improve healthcare for all parties.”

New Jersey’s life sciences sector is a major economic driver, employing over 105,000 people across pharmaceuticals, biotechnology, and medical device manufacturing as of 2020.

“New Jersey is home to approximately 4,300 life sciences establishments and a total of 113 hospitals, including specialty hospitals. Among these, there are 72 acute care hospitals.

“New Jersey’s partnership with ABHI is a testament to our commitment to driving innovation and expanding our life sciences sector,” said Wes Mathews, President & CEO of Choose New Jersey.

“With each engagement, from the September cohort’s visit to today’s roundtable, we’re strengthening New Jersey’s ties with UK HealthTech leaders and creating new avenues for collaboration.

“We look forward to welcoming ABHI’s trade delegation to New Jersey in 2025 and building on this momentum to bring new opportunities and advancements to both markets.”

Continue Reading
2 Comments

2 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Pregnancy

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.